Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5245725 | 1.00 | CYP2C19 (0.73) | CYP2C19RAB9AALDH1A1KMT2ATSHR | |
| SCHEMBL4619511 | 0.86 | CYP2C19 (0.70) | CYP2C19RAB9AALDH1A1KMT2ATSHR | |
| SCHEMBL30292753 | 0.85 | RAB9A (0.74) | CYP2C19RAB9AALDH1A1KMT2ATSHR | |
| SCHEMBL25770728 | 0.85 | RAB9A (0.74) | CYP2C19RAB9AALDH1A1KMT2ATSHR | |
| SCHEMBL612760 | 0.85 | CYP2C19 (1.00) | CYP2C19RAB9AALDH1A1KMT2ATSHR | |
| SCHEMBL5716992 | 0.84 | RAB9A (0.61) | CYP2C19RAB9AALDH1A1KMT2ATSHR | |
| SCHEMBL5717158 | 0.84 | RAB9A (0.61) | CYP2C19RAB9AALDH1A1KMT2ATSHR | |
| SCHEMBL5250351 | 0.83 | RAB9A (0.84) | CYP2C19RAB9AALDH1A1KMT2ATSHR | |
| SCHEMBL24072673 | 0.82 | RAB9A (0.98) | CYP2C19RAB9AALDH1A1KMT2ATSHR | |
| SCHEMBL5243114 | 0.82 | AKR1C3 (0.67) | ALDH1A1KMT2ATSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691846-B2 | Piperidine sulphonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691846-B2 | Piperidine sulphonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20130217729-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | US | disclosed |
| US-20130217729-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | US | disclosed |
| US-20130217729-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | US | disclosed |
| US-20120238602-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | KNUST HENNER (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238602-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | KNUST HENNER (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238602-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | KNUST HENNER (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8202888-B2 | Piperidine sulphonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202888-B2 | Piperidine sulphonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2252587-B1 | PIPERIDINE SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| CN-101918361-A | Piperidine sulfonamide derivatives | HOFFMANN LA ROCHE | 2010-12-15 | — | — | CN | disclosed |
| EP-2252587-A1 | PIPERIDINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009100994-A1 | PIPERIDINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009100994-A1 | PIPERIDINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | WO | disclosed |
| US-20090203736-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090203736-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090203736-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
| EP-1866285-A1 | 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. Hoffmann-Roche AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006094633-A1 | 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203736-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | CYP2C19 2203/4885RAB9A 2023/4885ALDH1A1 477/4885 |
| US-20120238602-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | CYP2C19 2203/4885RAB9A 2023/4885ALDH1A1 477/4885 |
| US-20130217729-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | CYP2C19 2203/4885RAB9A 2023/4885ALDH1A1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.